ArticleTobacco control2025
Tobacco product flavour policies in the USA.
Article in Tobacco control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Longitudinal Trends in Medicaid Hearing Aid Coverage for Adults in the United States: 2003-2023.American journal of audiology · 2026Article
- Standardising the measurement of cigar tax rates in the USA, 2010-2024.Tobacco control · 2026Article
- Article
- Where Do E-cigarette Users Buy Their E-cigarette Products? Results From a Nationally Representative Sample of Adult E-cigarette Users in the United States.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Article
- Recent trends in sales of electronic nicotine devices and oral nicotine pouches by flavour.Tobacco control · 2025Article
- Population coverage and comprehensiveness of flavoured tobacco sales restrictions in the USA, 2010-2023.Tobacco control · 2025Article
- Trends in menthol and non-menthol cigarette consumption in the US: 2009-2024.Tobacco control · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesCharacterise US residents' exposure to restrictions on sales of flavoured electronic nicotine delivery system (ENDS), cigars and menthol cigarettes across states and time, and assess correlations between these policies.
methodsFrom 2022 to 2024, we compiled flavour policy locations from advocacy groups and online searches, located corresponding legal texts and reviewed these to identify policy details, including effective dates. Using census data, we calculated the proportion of state residents covered by each policy quarterly from 2009 to 2024 and estimated correlations between them and cigarette taxes.
resultsBy January 2024, menthol cigarettes, flavoured cigars and flavoured ENDS sales restrictions covered 15.0%, 18.1% and 28.1% of US residents. About 1 in 10 US residents is subject to flavoured ENDS restrictions without concurrent restrictions on flavoured cigar and menthol cigarette sales. Strong correlations between flavour policy coverage and cigarette tax rates indicate a need to adjust for exposure to a range of tobacco control policies in analyses evaluating any one of these regulations' effects.
conclusionsWhile state and local adoption of restrictions on flavoured tobacco product sales has proliferated, flavour policy coverage for combustible tobacco products lags well behind that for ENDS. If this leads some people who vape flavoured ENDS to substitute towards flavoured cigars and/or menthol cigarettes, this policy combination could harm population health. POLICY IMPLICATIONS: Rapid implementation of proposed US Food and Drug Administration rules barring flavoured cigar and menthol cigarette sales is needed to ensure that regulation of more lethal, combustible tobacco products is not more lenient than restrictions on less harmful nicotine products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.